Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

37.55 +0.72 (+1.95%)

Delayed Quote Updated: 2:33 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 Next >

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

October 20, 2026

From Harmony Biosciences

Via GlobeNewswire

Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth

October 12, 2026

From Harmony Biosciences

Via GlobeNewswire

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

October 01, 2026

From Harmony Biosciences

Via GlobeNewswire

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

September 03, 2026

From Harmony Biosciences

Via GlobeNewswire

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

August 27, 2026

From Harmony Biosciences

Via GlobeNewswire

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

August 06, 2026

From Harmony Biosciences

Via GlobeNewswire

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

August 04, 2026

From Harmony Biosciences

Via GlobeNewswire

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

July 21, 2026

From Harmony Biosciences

Via GlobeNewswire

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

July 16, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

June 11, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Participate in Upcoming Investor Conferences

May 27, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

May 07, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

April 23, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

April 16, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

April 14, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

April 02, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

March 31, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Participate in Upcoming Investor Conferences

March 04, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

February 24, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

February 17, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

February 10, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG

December 16, 2025

From Beacon Biosignals

Via GlobeNewswire

Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

December 08, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

December 02, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

November 24, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

November 19, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Participate in Upcoming Investor Conferences

November 18, 2025

From Harmony Biosciences

Via Business Wire

Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

November 04, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

October 23, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.